ANQUR
A Multi-Center, Randomized, Double-Blind Placebo Controlled Multiple-Ascending Dose Study to Evaluate the Safety and Tolerability of QRL-201 in Amyotrophic Lateral Sclerosis
The primary objective of this study is to determine the safety and tolerability of multiple doses of QRL-201 in people living with ALS.
This first-in-human, Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of QRL-201 administered intrathecal (IT) to participants with Amyotrophic Lateral Sclerosis. Two dose escalation cohorts of 8 participants each, followed by an additional 48 participants, receiving the study drug in a 6:2 ratio of QRL-201 to placebo.
Further information for medical professionals can be found here: ClinicalTrials.gov
Study start: Februar 2025
Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult)
Status: recruiting active
Principal Investigator: Priv.-Doz. Dr. Patrick Weydt
Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE)
Venusberg-Campus 1, Gebäude 99, 53127 Bonn
Contact: